TJP1 and fatty liver disease: I3C treatment reduces body weight, hepatic steatosis, and systemic inflammation of HFD-fed mice, ameliorates insulin resistance, and significantly augments the expression of Claudin4, Occludin, and ZO-1 to enhance intestinal barrier protein function.